FR2714057B1
(fr)
*
|
1993-12-17 |
1996-03-08 |
Sanofi Elf |
Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
|
FR2741621B1
(fr)
*
|
1995-11-23 |
1998-02-13 |
Sanofi Sa |
Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
|
FR2742148B1
(fr)
*
|
1995-12-08 |
1999-10-22 |
Sanofi Sa |
Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
|
FR2758723B1
(fr)
*
|
1997-01-28 |
1999-04-23 |
Sanofi Sa |
Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
|
FR2761266B1
(fr)
*
|
1997-03-28 |
1999-07-02 |
Sanofi Sa |
Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
|
FR2761265B1
(fr)
*
|
1997-03-28 |
1999-07-02 |
Sanofi Sa |
Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
|
WO1999053917A1
(en)
|
1998-04-21 |
1999-10-28 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Cannabinoids as antioxidants and neuroprotectants
|
JP3852644B2
(ja)
|
1998-09-21 |
2006-12-06 |
チッソ株式会社 |
分割型複合繊維、これを用いた不織布及び吸収性物品
|
FR2789079B3
(fr)
|
1999-02-01 |
2001-03-02 |
Sanofi Synthelabo |
Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
|
FR2799124B1
(fr)
|
1999-10-01 |
2004-08-13 |
Sanofi Synthelabo |
Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
|
US7393842B2
(en)
*
|
2001-08-31 |
2008-07-01 |
University Of Connecticut |
Pyrazole analogs acting on cannabinoid receptors
|
FR2800372B1
(fr)
*
|
1999-11-03 |
2001-12-07 |
Sanofi Synthelabo |
Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
|
FR2804604B1
(fr)
*
|
2000-02-09 |
2005-05-27 |
Sanofi Synthelabo |
Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
|
JP2004502642A
(ja)
*
|
2000-02-11 |
2004-01-29 |
ブリストル−マイヤーズ スクイブ カンパニー |
カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
|
FR2809621B1
(fr)
*
|
2000-05-12 |
2002-09-06 |
Sanofi Synthelabo |
Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques
|
US20020091114A1
(en)
|
2000-10-04 |
2002-07-11 |
Odile Piot-Grosjean |
Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
|
FR2814678B1
(fr)
†
|
2000-10-04 |
2002-12-20 |
Aventis Pharma Sa |
Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
|
US8449908B2
(en)
|
2000-12-22 |
2013-05-28 |
Alltranz, Llc |
Transdermal delivery of cannabidiol
|
WO2003007887A2
(en)
|
2001-07-20 |
2003-01-30 |
Merck & Co., Inc. |
Substituted imidazoles as cannabinoid receptor modulators
|
FR2831883B1
(fr)
*
|
2001-11-08 |
2004-07-23 |
Sanofi Synthelabo |
Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
SE0104330D0
(sv)
|
2001-12-19 |
2001-12-19 |
Astrazeneca Ab |
Therapeutic agents
|
WO2003082190A2
(en)
|
2002-03-26 |
2003-10-09 |
Merck & Co., Inc. |
Spirocyclic amides as cannabinoid receptor modulators
|
FR2837706A1
(fr)
*
|
2002-03-28 |
2003-10-03 |
Sanofi Synthelabo |
Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles
|
CA2481313A1
(en)
|
2002-04-12 |
2003-10-23 |
Merck & Co., Inc. |
Bicyclic amides
|
US6825209B2
(en)
|
2002-04-15 |
2004-11-30 |
Research Triangle Institute |
Compounds having unique CB1 receptor binding selectivity and methods for their production and use
|
EP1523334A2
(en)
|
2002-07-18 |
2005-04-20 |
Cytos Biotechnology AG |
Hapten-carrier conjugates and uses thereof
|
US7402835B2
(en)
*
|
2002-07-18 |
2008-07-22 |
Chevron U.S.A. Inc. |
Heteroatom-containing diamondoid transistors
|
EP1532132B1
(en)
|
2002-07-29 |
2008-03-19 |
F.Hoffmann-La Roche Ag |
Novel benzodioxoles
|
AU2003275242B2
(en)
|
2002-09-27 |
2010-03-04 |
Merck Sharp & Dohme Corp. |
Substituted pyrimidines
|
GB0228417D0
(en)
*
|
2002-12-05 |
2003-01-08 |
Cancer Rec Tech Ltd |
Pyrazole compounds
|
RU2330035C2
(ru)
|
2003-01-02 |
2008-07-27 |
Ф.Хоффманн-Ля Рош Аг |
Пирролилтиазолы и фармацевтическая композиция, обладающая свойством модулятора рецептора св1
|
AU2003298227A1
(en)
|
2003-01-02 |
2004-07-29 |
F. Hoffmann-La Roche Ag |
Novel cb 1 receptour inverse agonists
|
TW200505902A
(en)
*
|
2003-03-20 |
2005-02-16 |
Schering Corp |
Cannabinoid receptor ligands
|
DE10314610A1
(de)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
JP2006527770A
(ja)
*
|
2003-06-18 |
2006-12-07 |
アストラゼネカ アクチボラグ |
Cb1モジュレーターとしての2−置換5,6−ジアリール−ピラジン誘導体
|
GB0314057D0
(en)
*
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
GB0314049D0
(en)
*
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
GB0314261D0
(en)
*
|
2003-06-19 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
ATE390922T1
(de)
|
2003-06-20 |
2008-04-15 |
Hoffmann La Roche |
2-aminobenzothiazole als cb1 rezeptor inverse agonisten
|
GB0327331D0
(en)
*
|
2003-11-25 |
2003-12-31 |
Astrazeneca Ab |
Therapeutic agents
|
CA2547804A1
(en)
|
2003-12-08 |
2005-06-30 |
F. Hoffmann-La Roche Ag |
Novel thiazole derivatives
|
FR2864958B1
(fr)
*
|
2004-01-12 |
2006-02-24 |
Sanofi Synthelabo |
Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.
|
EP1574211A1
(en)
|
2004-03-09 |
2005-09-14 |
Inserm |
Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
|
CA2564986A1
(en)
|
2004-05-10 |
2005-11-17 |
F. Hoffmann-La Roche Ag |
Pyrrole or imidazole amides for treating obesity
|
ITMI20041032A1
(it)
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Compositi farmaceutici
|
ITMI20041033A1
(it)
*
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Composti farmaceutici
|
AU2005278781B2
(en)
|
2004-07-12 |
2009-06-18 |
Cadila Healthcare Limited |
Tricyclic pyrazole derivatives as cannabinoid receptor modulators
|
FR2873372B1
(fr)
*
|
2004-07-22 |
2006-09-08 |
Sanofi Synthelabo |
Procede de preparation de derives n-piperidino-1,5- diphenylpyrazole-3-carboxamide
|
US20060025448A1
(en)
|
2004-07-22 |
2006-02-02 |
Cadila Healthcare Limited |
Hair growth stimulators
|
FR2874012B1
(fr)
*
|
2004-08-09 |
2008-08-22 |
Sanofi Synthelabo |
Derives de pyrrole, leur preparation et leur utlisation en therapeutique
|
AU2005298986A1
(en)
|
2004-10-27 |
2006-05-04 |
F. Hoffmann-La Roche Ag |
New indole or benzimidazole derivatives
|
BRPI0518241A
(pt)
|
2004-11-01 |
2008-04-22 |
Amylin Pharmaceuticals Inc |
métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
|
US8394765B2
(en)
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
ES2351348T3
(es)
|
2004-11-09 |
2011-02-03 |
F. Hoffmann-La Roche Ag |
Derivados de la dibenzosuberona.
|
AU2005303223A1
(en)
*
|
2004-11-15 |
2006-05-18 |
Taisho Pharmaceutical Co., Ltd. |
Imine compound
|
FR2880023B1
(fr)
|
2004-12-23 |
2007-02-23 |
Sanofi Aventis Sa |
Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
|
US20080234323A1
(en)
*
|
2005-01-06 |
2008-09-25 |
Braj Bhushan Lohray |
Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride
|
CA2594488C
(en)
*
|
2005-01-10 |
2015-04-28 |
University Of Connecticut |
Novel heteropyrrole analogs acting on cannabinoid receptors
|
US8853205B2
(en)
|
2005-01-10 |
2014-10-07 |
University Of Connecticut |
Heteropyrrole analogs acting on cannabinoid receptors
|
FR2881744B1
(fr)
|
2005-02-09 |
2007-04-27 |
Sanofi Aventis Sa |
Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
|
FR2882263B1
(fr)
|
2005-02-23 |
2007-04-06 |
Sanofi Aventis Sa |
Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales
|
FR2882262B1
(fr)
*
|
2005-02-23 |
2007-04-06 |
Sanofi Aventis Sa |
Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales
|
DE102005011050A1
(de)
|
2005-03-10 |
2006-09-21 |
Degussa Ag |
Verfahren zur Herstellung von 1-Aminopiperidinderivaten
|
RU2404164C2
(ru)
|
2005-04-06 |
2010-11-20 |
Ф.Хоффманн-Ля Рош Аг |
Производные пиридин-3-карбоксамида в качестве обратных агонистов св1
|
CN1310891C
(zh)
*
|
2005-05-19 |
2007-04-18 |
金鑫 |
N-哌啶基-1-(2,4-二氯苯基)-4-甲基-5-(4-氯苯基)吡唑-3-甲酰胺有机酸盐及其药物组合物
|
DE102005026762A1
(de)
|
2005-06-09 |
2006-12-21 |
Sanofi-Aventis Deutschland Gmbh |
Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
|
EP1910290A2
(en)
|
2005-06-30 |
2008-04-16 |
Prosidion Limited |
Gpcr agonists
|
FR2888236B1
(fr)
*
|
2005-07-08 |
2007-09-21 |
Sanofi Aventis Sa |
Derives de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique
|
EP1743637A1
(en)
|
2005-07-15 |
2007-01-17 |
Laboratorios Del Dr. Esteve, S.A. |
Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
|
GB0514739D0
(en)
*
|
2005-07-19 |
2005-08-24 |
Astrazeneca Ab |
Therapeutic agents
|
EP1752149A1
(en)
|
2005-07-29 |
2007-02-14 |
Laboratorios Del Dr. Esteve, S.A. |
CB1 Antagonists or inverse agonists as therapeutical agents for the treatment of inflammation involving gene expression
|
AU2006279680B2
(en)
|
2005-08-11 |
2012-12-06 |
Amylin Pharmaceuticals, Llc |
Hybrid polypeptides with selectable properties
|
EP2330125A3
(en)
|
2005-08-11 |
2012-12-12 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
KR20080048502A
(ko)
|
2005-09-29 |
2008-06-02 |
머크 앤드 캄파니 인코포레이티드 |
멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
|
JP5069894B2
(ja)
*
|
2005-10-21 |
2012-11-07 |
田辺三菱製薬株式会社 |
ピラゾール化合物
|
CN100999517B
(zh)
*
|
2006-01-11 |
2010-12-15 |
北京摩力克科技有限公司 |
吡唑甲酰胺衍生物,药物组合物和其制备方法
|
EP1816125A1
(en)
*
|
2006-02-02 |
2007-08-08 |
Ranbaxy Laboratories, Ltd. |
Novel crystalline forms of an antagonist of CB1 cannabinoid receptor and preparation method thereof
|
FR2897060B1
(fr)
*
|
2006-02-08 |
2008-07-25 |
Sanofi Aventis Sa |
Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
CN101062919B
(zh)
*
|
2006-04-26 |
2012-08-15 |
中国人民解放军军事医学科学院毒物药物研究所 |
4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
|
WO2007121687A1
(fr)
*
|
2006-04-26 |
2007-11-01 |
Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China |
Dérivés du 4-méthyl-1h-diaryl pyrazole et leur utilisation comme médicaments
|
FR2902008A1
(fr)
*
|
2006-06-07 |
2007-12-14 |
Sanofi Aventis Sa |
Utilisation d'un antagoniste des recepteurs cb1 aux cannabinoides pour la preparation de medicaments utiles pour la prevention et le traitement de l'hypertrophie begnine de la prostate
|
US7629346B2
(en)
|
2006-06-19 |
2009-12-08 |
Hoffmann-La Roche Inc. |
Pyrazinecarboxamide derivatives as CB1 antagonists
|
AR061606A1
(es)
*
|
2006-06-22 |
2008-09-10 |
Medichem Sa |
Formas solidas de rimonabant y procesos para su preparacion
|
SI2032521T1
(sl)
|
2006-06-27 |
2010-02-26 |
Sandoz Ag |
Nov postopek za pripravo soli
|
US7297710B1
(en)
|
2006-07-12 |
2007-11-20 |
Sanofi-Aventis |
Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide, their preparation and their application in therapeutics
|
AU2007283113A1
(en)
|
2006-08-08 |
2008-02-14 |
Sanofi-Aventis |
Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
|
WO2008026219A2
(en)
*
|
2006-09-01 |
2008-03-06 |
Hetero Drugs Limited |
Novel polymorphs of rimonabant
|
US7781593B2
(en)
|
2006-09-14 |
2010-08-24 |
Hoffmann-La Roche Inc. |
5-phenyl-nicotinamide derivatives
|
WO2008035023A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Cipla Limited |
Polymorphs of rimonabant
|
CA2664113C
(en)
|
2006-09-22 |
2013-05-28 |
Merck & Co., Inc. |
Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
|
WO2008056377A2
(en)
*
|
2006-11-06 |
2008-05-15 |
Cadila Healthcare Limited |
Polymorphic forms of rimonabant
|
FR2909090B1
(fr)
|
2006-11-23 |
2009-01-09 |
Sanofi Aventis Sa |
Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique.
|
CZ300115B6
(cs)
*
|
2006-12-01 |
2009-02-11 |
Zentiva, A. S. |
Zpusob výroby N-piperidino-5-(4-chlorfenyl)-1-(2,4-dichlorfenyl)-4-methylpyrazol-3-karboxamidu (rimonabantu)
|
WO2008064615A2
(en)
*
|
2006-12-01 |
2008-06-05 |
Zentiva, A.S. |
Crystalline and amorphous forms of rimonabant and processes for obtaining them
|
PE20081849A1
(es)
|
2007-01-04 |
2009-01-26 |
Prosidion Ltd |
Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
|
US20100048632A1
(en)
|
2007-01-04 |
2010-02-25 |
Matthew Colin Thor Fyfe |
Piperidine GPCR Agonists
|
GB0700122D0
(en)
|
2007-01-04 |
2007-02-14 |
Prosidion Ltd |
GPCR agonists
|
PE20081659A1
(es)
|
2007-01-04 |
2008-10-24 |
Prosidion Ltd |
Agonistas de gpcr
|
EP2114936A1
(en)
|
2007-01-04 |
2009-11-11 |
Prosidion Limited |
Piperidine gpcr agonists
|
US20080182877A1
(en)
*
|
2007-01-05 |
2008-07-31 |
Westheim Raymond J H |
Rimonabant forms and methods of making the same
|
FR2911136B1
(fr)
|
2007-01-05 |
2009-02-20 |
Sanofi Aventis Sa |
Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
|
EP1944297A1
(en)
*
|
2007-01-09 |
2008-07-16 |
Miklós Vértessy |
Solid and crystalline rimonabant and processes for preparation, and pharmaceutical composition thereof
|
EP1953144A1
(en)
*
|
2007-01-30 |
2008-08-06 |
Sandoz AG |
Novel polymorphic forms of N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolecarboxamide
|
WO2008102367A1
(en)
*
|
2007-02-19 |
2008-08-28 |
Darmesh Mahendrabhai Shah |
Process for preparation of pyrazole derivatives
|
WO2008101860A1
(en)
*
|
2007-02-20 |
2008-08-28 |
Sandoz Ag |
Novel process for the preparation of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-(piperidin-1-yl)pyrazole-3-carboxamide
|
FR2913018A1
(fr)
*
|
2007-02-23 |
2008-08-29 |
Sanofi Aventis Sa |
Solution solide amorphe contenant un derive de pyrazole-3-carboxamide sous forme amorphe et des excipients stabilisateurs
|
WO2008120653A1
(ja)
|
2007-04-02 |
2008-10-09 |
Banyu Pharmaceutical Co., Ltd. |
インドールジオン誘導体
|
JP4994295B2
(ja)
*
|
2007-04-20 |
2012-08-08 |
田辺三菱製薬株式会社 |
医薬組成物
|
CN101302200B
(zh)
*
|
2007-05-09 |
2011-04-20 |
上海医药工业研究院 |
制备n-哌啶子基-5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基吡唑-3-甲酰胺的方法
|
FR2919184A1
(fr)
*
|
2007-07-26 |
2009-01-30 |
Sanofi Aventis Sa |
L'acide 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4- methylpyrazole-3-carboxylique, ses esters, ses sels pharmaceutiquement acceptables et leurs solvates pour leur utilisation comme medicament.
|
FR2919864A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de 1,4-dioxane de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919865A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de dmso de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919861A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate d'isopranol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919868A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de n,n-dimethyformamide de rimonabant, et son procede de preparation
|
FR2919867A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de 2-methoxyethanol de rimonabant et son procede de preparation
|
FR2919862A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de 3-methylbutan-1-ol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919866A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de methanol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919863A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de n-methylpyrrolidone de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
GB0720390D0
(en)
|
2007-10-18 |
2007-11-28 |
Prosidion Ltd |
G-Protein coupled receptor agonists
|
GB0720389D0
(en)
|
2007-10-18 |
2008-11-12 |
Prosidion Ltd |
G-Protein Coupled Receptor Agonists
|
DE102007054497B3
(de)
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
WO2009109222A1
(en)
*
|
2008-03-04 |
2009-09-11 |
Maprimed, S. A. |
Process for the preparation of rimonabant
|
WO2009153804A1
(en)
*
|
2008-06-16 |
2009-12-23 |
Cadila Healthcare Limited |
Process for preparing form i of rimonabant
|
UY31968A
(es)
|
2008-07-09 |
2010-01-29 |
Sanofi Aventis |
Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
WO2010079241A1
(es)
*
|
2009-01-12 |
2010-07-15 |
Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion |
Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
|
US10053444B2
(en)
|
2009-02-19 |
2018-08-21 |
University Of Connecticut |
Cannabinergic nitrate esters and related analogs
|
KR20120060207A
(ko)
|
2009-08-26 |
2012-06-11 |
사노피 |
신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
US8410107B2
(en)
|
2010-10-15 |
2013-04-02 |
Hoffmann-La Roche Inc. |
N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
|
US8669254B2
(en)
|
2010-12-15 |
2014-03-11 |
Hoffman-La Roche Inc. |
Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
|
US8710050B2
(en)
|
2011-03-08 |
2014-04-29 |
Sanofi |
Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
EP2683703B1
(de)
|
2011-03-08 |
2015-05-27 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8828995B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
WO2012120050A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
WO2012120052A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2683705B1
(de)
|
2011-03-08 |
2015-04-22 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
EP2683700B1
(de)
|
2011-03-08 |
2015-02-18 |
Sanofi |
Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
WO2012120051A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
WO2012120058A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
CN102206182B
(zh)
*
|
2011-04-11 |
2013-03-13 |
中国药科大学 |
盐酸利莫那班的合成方法
|
AR087701A1
(es)
|
2011-08-31 |
2014-04-09 |
Japan Tobacco Inc |
Derivados de pirazol con actividad inhibidora de sglt1
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
RU2600983C2
(ru)
*
|
2011-09-30 |
2016-10-27 |
Нэшнл Хелт Рисерч Инститьютс |
Производные соединения пиразола
|
AU2015269247B2
(en)
|
2014-06-06 |
2019-10-24 |
Research Triangle Institute |
Apelin receptor (APJ) agonists and uses thereof
|
BR112018011784A2
(pt)
|
2015-12-09 |
2018-12-04 |
Res Triangle Inst |
agonistas aprimorados do receptor de apelina (apj) e usos dos mesmos
|
CA3125847A1
(en)
|
2020-07-27 |
2022-01-27 |
Makscientific, Llc |
Process for making biologically active compounds and intermediates thereof
|
US12054480B2
(en)
|
2020-07-31 |
2024-08-06 |
Makscientific, Llc |
Compounds for treating cannabinoid toxicity and acute cannabinoid overdose
|
PT4000621T
(pt)
|
2020-11-18 |
2023-07-07 |
Fundacion Del Hospital Nac De Paraplejicos Para La Investigacion Y La Integracion |
Utilização de antagonistas e/ou agonistas inversos de recetores cb1 para preparar medicamentos para tratar síndrome de fadiga pós-viral
|